1,380
Participants
Start Date
February 15, 2007
Primary Completion Date
October 2, 2007
Study Completion Date
October 2, 2007
Telcagepant potassium 150 mg
Telcagepant 150 mg liquid-filled soft gel capsules
Telcagepant potassium 300 mg
Telcagepant 300 mg liquid-filled soft gel capsules
Zolmitriptan 5 mg
Zolmitriptan 5 mg tablets
Placebo to telcagepant 150 mg
Placebo to match telcagepant 150 mg liquid-filled soft gel capsules
Placebo to tecagepant 300 mg
Placebo to match tecagepant 300 mg liquid-filled soft gel capsules
Placebo to zolmitriptan 5 mg
Placebo to match zolmitriptan 5 mg tablets
Rescue medication
If moderate or severe migraine headache pain continues or recurs 2 hours after dose of study drug, participants are allowed to take an optional second dose of study drug or their own non-study rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\] or opiates), anti-emetics, or zolmitriptan. Triptans other than zolmitriptan and ergot derivatives are prohibited for 24 hours following the last dose of study drug.
Merck Sharp & Dohme LLC
INDUSTRY